What companies are developing CNS drugs in China?

Several pharmaceutical and biotechnology companies in China are actively involved in the research and development of Central Nervous System (CNS) drugs. Some prominent companies in this space include:

Hutchison China MediTech (Chi-Med): 

Chi-Med is a leading innovative biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for oncology and immunological diseases. The company has a growing pipeline of potential CNS drug candidates.

Innovent Biologics: 

Innovent Biologics is dedicated to the discovery, development, manufacturing, and commercialization of high-quality biopharmaceutical products. While the company's primary focus is on oncology and autoimmune diseases, it also has initiatives in CNS drug development.

Shanghai Green Valley Pharmaceuticals: 

Green Valley Pharmaceuticals is engaged in the research and development of novel drugs for the treatment of CNS disorders, including neurodegenerative diseases and mental health conditions.

Shanghai Hengrui Pharmaceutical Co., Ltd.: 

Hengrui Pharmaceutical is a leading Chinese pharmaceutical company with a diverse portfolio of innovative medicines. The company is involved in CNS drug R&D, particularly in areas such as neurology and psychiatry.

Jiangsu Simcere Pharmaceutical Group: 

Simcere Pharmaceutical is known for its research and development efforts in the fields of oncology, neurology, and other therapeutic areas. The company has been involved in the development of CNS drugs targeting various neurological and psychiatric disorders.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: 

Fosun Pharmaceutical is a major healthcare company with a broad range of pharmaceutical and healthcare businesses. The company has invested in CNS drug research and development as part of its larger pharmaceutical activities.

These companies, among others, are contributing to the advancement of CNS drug discovery and development in China. Their efforts encompass a wide spectrum of neurological and psychiatric conditions, including neurodegenerative diseases, mental health disorders, epilepsy, and others. Through their research and innovation, these companies aim to address unmet medical needs and improve the quality of life for patients affected by CNS diseases.